공고 • Jul 10
Ocumetics Technology Corp. Reports Positive Six-Month Results and Advances Next-Generation Ocumetics Lens to Group Two Clinical Surgeries Ocumetics Technology Corp. reported positive six-month results from its First-in-Human clinical study, supporting advancement to Group Two clinical surgeries. Positive six-month clinical data have supported progression to Group Two surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced, regulatory milestones have been achieved, and strategic engagement with leading global ophthalmic companies continue to build momentum. Six-month follow-up data from Group One patients enrolled in the Company's First-in-Human clinical study continues to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered to be legally blind that is now qualified to drive. These positive clinical outcomes have provided the foundation necessary for Ocumetics to advance to the second group of its First-in-Human study (Group Two), representing another significant milestone toward commercialization. Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens. The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production. Expected benefits of the redesigned Ocumetics Lens include: Enhanced accommodative performance. Simplified lens architecture with one-piece design. Improved manufacturing consistency. Elimination of internal interface materials. No air, water or oil. Optimized surgical implantation characteristics. Improved compatibility with the redesigned lens delivery system. Greater scalability for commercial manufacturing. The Company intends to use this redesigned lens for the upcoming Group Two First-in-Human study surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced with the Company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of the planned Third Quarter 2026 clinical surgeries. Ocumetics has successfully completed all regulatory requirements necessary to proceed to Group Two patient enrollment. Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will commence. Group Two patients are expected to receive the redesigned Ocumetics Lens delivered with the Company's updated lens delivery system. The Ocumetics Lens and the lens delivery system each incorporate improvements developed through previous preclinical work and feedback from the Group One First-in-Human surgery experience. 공고 • Jul 08
Ocumetics Technology Corp. announced that it expects to receive CAD 2 million in funding Ocumetics Technology Corp .announced to issue up to 5,000,000 units of the Corporation at a price of CAD 0.40 per Unit for gross proceeds of up to CAD 2,000,000. There will be no minimum subscription level for the Offering. Each Unit will consist of one common share in the share capital of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.50 for a period of three years from the date of issuance of the Warrant. The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least CAD 0.75 per Common Share for a period of 30 consecutive trading days, the expiry date of the Warrants may be accelerated by the Corporation to a date that is not less than 30 days after the date that notice of such acceleration is provided to the Warrant holders by way of a press release. The Offering may include finder’s fees commissions payable in cash and/or securities and is subject to approval of the TSX Venture Exchange. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. Insiders may participate in the Offering. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions but is expected to be exempt from the formal valuation and minority shareholder
approval requirements of that instrument. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director James Mcroberts was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Apr 29
Ocumetics Technology Corp. announced that it expects to receive CAD 1.54 million in funding Ocumetics Technology Corp announced a private placement of up to 2,800,000 units of the Corporation at a price of CAD 0.55 per Unit for gross proceeds of up to CAD 1,540,000 on April 29, 2026. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.75 for a period of three years from the date of issuance of the Warrant. The Corporation may pay finders fees to those who assist the Corporation in filling the Private Placement. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. 공고 • Dec 24
Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026 Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026. 공고 • Jul 10
Ocumecs Technology Corp. Completes Staff Training for First-In-Human Clinical Study of Accommodaing Intraocular Lens Ocume cs Technology Corp. announced that it has completed training of the clinical team at its first study site in Mexico City. This training is in preparation for the upcoming first-in-human (FIH) clinical study of the Ocumetics accommodating intraocular lens. This training marks a critical milestone in Ocumetics' 18-year journey toward regulatory approval of a transformative accommodating intraocular lens technology intended to restore vision for patients undergoing cataract extraction. The training program is designed to ensure that all participating staff members are equipped with the specialized skills and knowledge necessary to implant the Ocumetics Lens with precision and safety. The Ocumetics Lens is designed to restore the ability to see both distant and near objects clearly without glasses following cataract surgery. The training program covers every phase of the clinical trial process, including pre-operative assessment, lens handling, surgical technique, and post-operative care. Using proven training methods, the curriculum ensures successful execution of the first clinical study of this novel technology. With clinical team training completed, and ethics committee approval pending, Ocumetics is poised to launch its historic FIH trial-an essential step toward clinical validation and eventual regulatory approval to market the Ocumetics Lens. 
